S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30

scPharmaceuticals Stock Forecast, Price & News

-0.03 (-0.74%)
(As of 01/24/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
66,377 shs
Average Volume
53,878 shs
Market Capitalization
$110.24 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive SCPH News and Ratings via Email

Sign-up to receive the latest news and ratings for scPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

scPharmaceuticals logo

About scPharmaceuticals

scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include furosemide, used as parenteral diuretic in treating heart failure and ceftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$3.01 per share


Net Income
$-32.21 million
Pretax Margin




Free Float
Market Cap
$110.24 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.03 out of 5 stars

Medical Sector

610th out of 1,415 stocks

Pharmaceutical Preparations Industry

294th out of 683 stocks

Analyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -

scPharmaceuticals (NASDAQ:SCPH) Frequently Asked Questions

Is scPharmaceuticals a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for scPharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" scPharmaceuticals stock.
View analyst ratings for scPharmaceuticals
or view top-rated stocks.

How has scPharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

scPharmaceuticals' stock was trading at $7.77 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SCPH stock has decreased by 48.1% and is now trading at $4.03.
View which stocks have been most impacted by COVID-19

When is scPharmaceuticals' next earnings date?

scPharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 22nd 2022.
View our earnings forecast for scPharmaceuticals

How were scPharmaceuticals' earnings last quarter?

scPharmaceuticals Inc. (NASDAQ:SCPH) released its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.07.
View scPharmaceuticals' earnings history

What price target have analysts set for SCPH?

2 equities research analysts have issued twelve-month price objectives for scPharmaceuticals' shares. Their forecasts range from $5.00 to $15.00. On average, they expect scPharmaceuticals' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 148.1% from the stock's current price.
View analysts' price targets for scPharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are scPharmaceuticals' key executives?

scPharmaceuticals' management team includes the following people:
  • John H. Tucker, President, Chief Executive Officer, CFO & Director (LinkedIn Profile)
  • Mike Hassman, Senior Vice President-Technical Operations
  • John Mohr, Senior VP-Clinical Development & Medical Affairs
  • Rachael Nokes, Chief Accounting Officer & SVP-Finance
  • Katherine Taudvin, Director-IR & Corporate Development

What other stocks do shareholders of scPharmaceuticals own?

When did scPharmaceuticals IPO?

(SCPH) raised $96 million in an IPO on Friday, November 17th 2017. The company issued 6,400,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

What is scPharmaceuticals' stock symbol?

scPharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH."

Who are scPharmaceuticals' major shareholders?

scPharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Thomasville National Bank (0.05%). Company insiders that own scPharmaceuticals stock include Andrew J Schwab, Jack A Khattar, John H Tucker and Ra Capital Management, LP.
View institutional ownership trends for scPharmaceuticals

Which institutional investors are buying scPharmaceuticals stock?

SCPH stock was purchased by a variety of institutional investors in the last quarter, including Thomasville National Bank. Company insiders that have bought scPharmaceuticals stock in the last two years include Andrew J Schwab, Jack A Khattar, John H Tucker, and Ra Capital Management, LP.
View insider buying and selling activity for scPharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of scPharmaceuticals?

Shares of SCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is scPharmaceuticals' stock price today?

One share of SCPH stock can currently be purchased for approximately $4.03.

How much money does scPharmaceuticals make?

scPharmaceuticals has a market capitalization of $110.24 million. The company earns $-32.21 million in net income (profit) each year or ($1.04) on an earnings per share basis.

How many employees does scPharmaceuticals have?

scPharmaceuticals employs 27 workers across the globe.

What is scPharmaceuticals' official website?

The official website for scPharmaceuticals is www.scpharma.com.

Where are scPharmaceuticals' headquarters?

scPharmaceuticals is headquartered at 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830.

How can I contact scPharmaceuticals?

scPharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The company can be reached via phone at (617) 517-0730 or via email at [email protected].

This page was last updated on 1/25/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.